Curriculum Vitae Prof. Dr. Matthias Tschöp

Image: Matthias Tunger | Helmholtz Munich

Name:	**Matthias H. Tschöp**
Born:	**7 April 1967**

Research Priorities: Metabolic disease, prevention and treatment of obesity and diabetes, gut-brain communication, insulin resistance, drug research

Matthias Tschöp is a German physician-scientist and is considered one of the leading international scientists for diabetes and obesity. He unraveled fundamental gut-brain signals to discover medicines capable of normalizing body weight, the dual and triple gut hormone multi-agonists. A first representative is FDA-approved, others are successfully progressing through clinical trials. Offering more than 20% body weight loss and unprecedented blood sugar control, these new medicines enable the reversal of the obesity and diabetes pandemic, a scientific achievement previously believed to be impossible.

Academic and Professional Career

since 2023	Vice President of Health Research, Helmholtz Association of German Research Centers, Germany
since 2018	Chief Executive Officer and Chief Scientific Officer, Helmholtz Munich, Munich, Germany
since 2012	Adjunct Professor, Yale University, New Haven, USA
since 2012	Alexander von Humboldt Professor and Chair, Division of Metabolic Diseases, Technical University of Munich, Munich, Germany
2017 - 2020	Founding Director, Helmholtz Pioneer Campus, Munich, Germany
2011 - 2018	Founding and Scientific Director, Helmholtz Diabetes Center, Helmholtz Munich, Munich, Germany

2011 - 2018	Founding Director, Institute for Diabetes and Obesity, Helmholtz Munich, Munich, Germany and Research Director, Helmholtz Diabetes Center, Munich, Germany
2009 - 2011	Arthur Russell Morgan Chair of Medicine, College of Medicine, University of Cincinnati, Cincinnati, USA
2009 - 2011	Research Director, Cincinnati Diabetes and Obesity Centre, College of Medicine, University of Cincinnati, Cincinnati, USA
2009 - 2011	Professor, Institute for Metabolic Diseases, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Cincinnati, Cincinnati, USA
2003 - 2013	Visiting Scientist, Department Pharmacology, German Institute for Human Nutrition Potsdam-Rehbrücke, Nuthetal, Germany
2003 - 2009	Associate Professor (Tenure since 2007), Obesity Research Center and Genome Research Institute, Department of Psychiatry and Medicine, University of Cincinnati, Cincinnati, USA
2002 - 2003	Senior Scientist, Department Pharmacology, German Institute for Human Nutrition Potsdam-Rehbrücke, Nuthetal, Germany
1999 - 2002	Postdoc, Discovery Research, Lilly Research Laboratories, Eli Lilly and Co., Indianapolis, USA
1995 - 1999	Researcher, Neuroendocrinology Working Group, Clinic City Centre, LMU Munich, Munich, Germany
1998	MD in Medicine, LMU Munich, Munich, Germany
1995 - 1999	Assistant Physician, Clinic City Centre, LMU Munich, Munich, Germany
1987 - 1994	Studies in Medicine (pre-medical and medical school, internship in internal medicine, surgery and psychiatry), LMU Munich, Munich, Germany

Functions in Scientific Societies and Committees (Selection)

since 2023	Member, Progamme Committee, EASD 60th Annual Meeting, Madrid, Spain
since 2023	Chair, Founding Committee of the Carl and Gerty Cori Institute of Molecular Metabolism, Austrian Academy of Sciences, Graz, Austria
since 2023	Member, Scientific Advisory Board, MRC London Institute of Medical Sciences, London, UK
since 2022	Member, Commission on Clinical Obesity, The Lancet, UK
since 2022	Member, National Committee for Health Research (Forum Gesundheit), Federal Ministry of Education and Research, Germany

since 2021	Member, Advisory Board, Comprehensive Cancer Center (CCC) Munich, Munich, Germany
since 2014	Scientific Advisory Board, Max Planck Institute for Metabolism Research, Cologne, Germany

Honours and Awarded Memberships (Selection)

2023	Heinrich Wieland Prize, Boehringer Ingelheim Foundation, Mainz, Germany
2023	Ernst Schering Prize, Schering Stiftung, Berlin, Germany
2023	Banting Medal, American Diabetes Association (ADA), USA
2022	EASD-Lilly Centennial Anniversary Prize, European Association for the Study of Diabetes
since 2022	Elected Member, Association of American Physicians (AAP), USA
2021	Ernst Jung Prize for Medicine, Jung Foundation (Jung-Stiftung für Wissenschaft und Forschung), Hamburg, Germany
2021	Berthold Medal, German Society of Endocrinology (DGE)
since 2020	Elected Member, European Molecular Biology Organization (EMBO)
2019	Paul Langerhans Medal, German Diabetes Association, Germany
since 2018	Elected Member, Bavarian Academy of Sciences and Humanities, Germany
2017	Outstanding Innovation Award, Endocrine Society, Washington D.C., USA
2017	Charles H. Best Lectureship and Award, University of Toronto, Toronto, Canada
2017	Carus Medal, German National Academy of Sciences Leopoldina, Germany
2017	Carus Prize, Stadt Schweinfurt, Germany
2017	Hansen Family Award, Bayer Foundation, Leverkusen, Germany
2017	Rolf Sammet Guest Professorship, Goethe University Frankfurt/Main, Frankfurt/Main, Germany
2017	Honorary Doctorate Degree (Dr. h.c.), University of Leipzig, Leipzig, Germany
since 2016	Elected Member, Academia Europaea (AE)
2016	European Medal, Society for Endocrinology
2014	Erwin Schrödinger Prize, The Stifterverband, Essen, Germany
2014	Paul Martini Prize, Paul Martini Foundation, Berlin, Germany

2014	Linda and Jack Gill Distinguished Scientist Award, Gill Center for Biomolecular Science, Indiana University Bloomington, Bloomington, USA
since 2013	Member, German National Academy of Sciences Leopoldina, Germany
2012	Werner Creutzfeld Award, German Diabetes Society
2012	Alexander von Humboldt Professorship, Alexander von Humboldt Foundation, Bonn, Germany
2011	Outstanding Scientific Achievement Award, American Diabetes Association, USA
2010	NIDDK 60th Anniversary Scholar Award, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH), USA
2010	André Mayer Award, International Association for the Study of Obesity (IASO)
since 2009	Elected Member, American Society for Clinical Investigation (ASCI), USA
2007	Scientific Achievement Award, The Obesity Society (TOS), Rockville, USA

Research Priorities

Matthias Tschöp is a German physician-scientist and is considered one of the leading international scientists for diabetes and obesity. He unraveled fundamental gut-brain signals to discover medicines capable of normalizing body weight, the dual and triple gut hormone multi-agonists. A first representative is FDA-approved, others are successfully progressing through clinical trials. Offering more than 20 ercent body weight loss and unprecedented blood sugar control, these new medicines enable the reversal of the obesity and diabetes pandemic, a scientific achievement previously believed to be impossible.

As a physician-scientist, Matthias Tschöp embarked on a mission to discover effective therapeutics for obesity and identified the hunger hormone: Ghrelin. This breakthrough revealed a fundamental metabolic control signal. Recognizing that one signal would not be sufficient to effectively reverse obesity, Matthias Tschöp then started to combine several hormone action profiles into single hybrid molecules. Together with the chemist Richard DiMarchi, he created dual and triple hormone-like peptides by strategically choosing specific amino acids from a pool of metabolically active gut hormones (e.g. GIP, GLP-1, Glucagon) as well as adding modifications to increase half-life, stability and solubility. The result was a new class of therapeutics, offering unprecedented levels of metabolic benefits and weight loss in obesity. Tschöp and DiMarchi then validated the first types of these poly-agonists in rodent and primate models and led the very first clinical tests.

Today, numerous pharmaceutical companies are advancing versions of these co-agonists through clinical trials. The FDA-approved first representative of this drug class, Tirzepatide ("Mounjaro", Eli Lilly & Co), already achieves an average weight loss of 22.5% in human obesity and delivers unprecedented benefits in diabetes. In aggregate Matthias Tschöp pioneered a new era of

metabolic medicine: For the first time, human obesity can be effectively treated, significantly reducing the risk for diabetes and enabling the reversal of a global pandemic.